IN THE NEWS
-
WHAT'S NEW FOR MERCURY?
Latest update: MERCURY™ v3.0 We are delighted to present the new version of MERCURY (v3.0). This release includes a number of updates... Read More
-
AGREEMENT ON A FRIENDLY TAKEOVER BID BY ONCODNA FOR INTEGRAGEN
Agreement on a friendly takeover bid by ONCODNA for INTEGRAGEN at €2.20 per share, for the entire share capital. This operation would combine... Read More
-
INTEGRAGEN - S1 2020 SALES OF €4.7M UP +13 % AND CASH POSITION OF €5.8M
IntegraGen today announces its sales, unaudited, for the first half of 2020. Unaudited sales for the first half amounted to €4,706K, up... Read More
LATEST NEWS
-
INTEGRAGEN UPDATE - ALWAYS OPEN FOR YOUR PROJECTS
IntegraGen is following government recommendations and precautionary measures related to the... Read More
-
INTEGRAGEN - ANNUAL RESULTS 2019
Sales growth (+201TP3Q), EBITDA positive in the second half and close to... Read More
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, to... Read More
-
COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY
Dear IntegraGen customers and partners, We care about your satisfaction and understand that all... Read More
